Dongguan Dongyangguang Taijing Pharmaceutical Research and Development

Dongguan Dongyangguang Taijing Pharmaceutical is a specialized research and development company based in Dongguan, China, operating as a joint venture between Sunshine Lake Pharma (HEC Pharm) and TaiGen Biopharmaceuticals. The company is primarily dedicated to the development and commercialization of innovative antiviral therapies, with a specific focus on chronic Hepatitis C virus (HCV) infections. Its flagship products include the NS3/4A protease inhibitor furaprevir and the NS5A inhibitor yimitasvir, which together form a highly effective all-oral interferon-free treatment regimen. By leveraging the drug discovery expertise of TaiGen and the extensive clinical and manufacturing infrastructure of HEC Pharm, the company has successfully navigated the regulatory landscape in China to bring novel treatments to market. The entity plays a critical role in HEC Pharm's broader portfolio of infectious disease treatments, contributing to the advancement of public health in the region.